Phathom Pharmaceuticals, Inc.

PHAT

NASDAQ

Healthcare

Biotechnology

Florham Park, NJ, US427 employeesphathompharma.com

$11.35

+0.21(1.9%)

52W $2.29 – $18.08

AI-generated

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.

Revenue breakdown: Voquezna Product (100%).

$894MMkt Cap

$189MRev TTM

-$239MNI TTM

-3.5xP/E TTM

Latest Earnings

10-K

FY FY2025Feb 25, 2026

10-K for FY2025 was filed on 2026-02-26. AI summary is not available yet.

Read full analysis View SEC Filing

What Changed Recently

Financial Results

Feb 25, 2026

Results of Operations and Financial Condition. On February 26, 2026, Phathom Pharmaceuticals, Inc. issued a press release announcing its financial results for t

View filing →

Other Event

Jan 7, 2026

Other Events. On January 7, 2026, Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement

View filing →

Financial Results

Jan 6, 2026

of this Form 8-K shall be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall be deemed

View filing →

View all recent events →

Fundamentals

How The Business Makes Money

Revenue by Segment

Voquezna Product100%($230M)

Analyst View

Peer Companies

Company	Price	Change	Market Cap	P/E
KODKodiak Sciences Inc.	$40.55	-5.28%	$2.1B	-5.4
ANABAnaptysBio, Inc.	$57.98	+2.20%	$1.7B	-131.7
OCSOculis Holding AG	$26.48	-2.03%	$1.5B	-11.0
NRIXNurix Therapeutics, Inc.	$15.51	+0.16%	$1.3B	-5.3
BCAXBicara Therapeutics Inc. ...	$21.48	+4.78%	$1.2B	-8.3
SEPNSepterna, Inc.	$25.20	+3.43%	$1.1B	-21.5
XNCRXencor, Inc.	$12.79	+2.11%	$938M	-9.7
URGNUroGen Pharma Ltd.	$18.84	-0.53%	$917M	-5.5

Company Profile

CIK0001783183

ISINUS71722W1071

CUSIP71722W107

Phone877 742 8466

Address100 Campus Drive, Florham Park, NJ, 07932, US

SEC EDGAR